To the Editor I would like to offer 2 points to expand on the important analysis by Sarkar and colleagues.1 First, use of a single prostate-specific antigen (PSA) multiplier for all men using 5α-reductase inhibitors (5-ARIs) is probably not optimal. The goal is to estimate what each man’s PSA would have been in the absence of drug treatment. However, because 5-ARIs inhibit the common age-associated increase in gland volume and PSA, the PSA trajectory for a man being treated with a drug vs his counterfactual trajectory with no drug diverge over time. Furthermore, the benign prostatic hyperplasia component of total PSA would be higher in an older man vs a younger one. Therefore, a larger multiplier may be optimal in older men with longer-term 5-ARI exposure to further avoid delayed diagnosis. Alternatively, men taking 5-ARIs could benefit from monitoring with newer biomarkers that are less sensitive to alterations in androgen levels, such as urinary PCA3 or ERG fusion assays.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Gann PH. Benefits of Targeted Use of 5α-Reductase Inhibitors in Patients With Prostate Cancer. JAMA Intern Med. 2019;179(10):1441. doi:10.1001/jamainternmed.2019.3617
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: